Correlation Between Molecular Partners and Mineralys Therapeutics,

Can any of the company-specific risk be diversified away by investing in both Molecular Partners and Mineralys Therapeutics, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Molecular Partners and Mineralys Therapeutics, into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Molecular Partners AG and Mineralys Therapeutics, Common, you can compare the effects of market volatilities on Molecular Partners and Mineralys Therapeutics, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Molecular Partners with a short position of Mineralys Therapeutics,. Check out your portfolio center. Please also check ongoing floating volatility patterns of Molecular Partners and Mineralys Therapeutics,.

Diversification Opportunities for Molecular Partners and Mineralys Therapeutics,

-0.76

Correlation Coefficient

Molecular Partners  Mineralys Therapeutics,

Pay attention - limited upside

The 3 months correlation between Molecular and Mineralys is -0.76. Overlapping area represents the amount of risk that can be diversified away by holding Molecular Partners AG and Mineralys Therapeutics, Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Mineralys Therapeutics, and Molecular Partners is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Molecular Partners AG are associated (or correlated) with Mineralys Therapeutics,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Mineralys Therapeutics, has no effect on the direction of Molecular Partners i.e., Molecular Partners and Mineralys Therapeutics, go up and down completely randomly.

Pair Corralation between Molecular Partners and Mineralys Therapeutics,

Given the investment horizon of 90 days Molecular Partners AG is expected to under-perform the Mineralys Therapeutics,. But the stock apears to be less risky and, when comparing its historical volatility, Molecular Partners AG is 1.66 times less risky than Mineralys Therapeutics,. The stock trades about -0.1 of its potential returns per unit of risk. The Mineralys Therapeutics, Common is currently generating about 0.02 of returns per unit of risk over similar time horizon. If you would invest  1,305  in Mineralys Therapeutics, Common on January 6, 2025 and sell it today you would lose (65.00) from holding Mineralys Therapeutics, Common or give up 4.98% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Weak
Accuracy	100.0%
Values	Daily Returns

Molecular Partners AG  vs.  Mineralys Therapeutics, Common

Molecular Partners

Risk-Adjusted Performance

Very Weak

Over the last 90 days Molecular Partners AG has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of inconsistent performance in the last few months, the Stock's essential indicators remain very healthy which may send shares a bit higher in May 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Mineralys Therapeutics,

Risk-Adjusted Performance

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Mineralys Therapeutics, Common are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively conflicting basic indicators, Mineralys Therapeutics, may actually be approaching a critical reversion point that can send shares even higher in May 2025.

Pair Trading with Molecular Partners and Mineralys Therapeutics,

The main advantage of trading using opposite Molecular Partners and Mineralys Therapeutics, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Molecular Partners position performs unexpectedly, Mineralys Therapeutics, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mineralys Therapeutics, will offset losses from the drop in Mineralys Therapeutics,'s long position.

The idea behind Molecular Partners AG and Mineralys Therapeutics, Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.